Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease.
about
S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 PathwayThe impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort studyInsights on aging and exceptional longevity from longitudinal data: novel findings from the Framingham Heart Study.Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus.Anemia is associated with the progression of white matter disease in older adults with high blood pressure: the cardiovascular health studyAnaemia, haemoglobin level and cause-specific mortality in people with and without diabetes.Cardiovascular and Renal Links along the Cardiorenal ContinuumAnemia and microvascular complications in patients with type 2 diabetes mellitusAssociation between ischemic stroke and iron-deficiency anemia: a population-based study.The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysisHepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease.Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination SurveyThe Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease.Associations between hemoglobin concentrations and the clinical characteristics of patients with type 2 diabetes.Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults.Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional StudyMortality rates in trials of subjects with type 2 diabetes.Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition StudyIncreased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease.Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study.Can Serum Gdf-15 be Associated with Functional Iron Deficiency in Hemodialysis Patients?High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.Anaemia and kidney dysfunction in Caribbean type 2 diabetic patients.Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.Anemia, diabetes, and chronic kidney disease.Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial.Association between dietary iron, iron stores, and serum lipid profile in reproductive age women.Statins in patients with chronic kidney disease: why, who and when?How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.Hospitalization and 1-year all-cause mortality in type 2 diabetic patients with chronic kidney disease at Stages 1 and 2: Effect of mild anemia.Association of Anemic Hypoxia and Increased Pulmonary Artery Systolic Pressure in Patients With Systemic Lupus Erythematosus.Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes.Anemia: A significant cardiovascular mortality risk after ST-segment elevation myocardial infarction complicated by the comorbidities of hypertension and kidney disease.High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease.[Self-reported diabetes in the elderly: prevalence, associated factors, and control practices].An Update on AMPK in Hydrogen Sulfide Pharmacology.
P2860
Q28554256-58845AF2-6F38-4547-AB68-5A62AE3E263DQ30883735-2FC63664-36E8-41B0-BBBA-8274929A75C9Q31131033-ABDF0186-3E4D-4DAD-A087-5CADFDCB559CQ33585503-8FC746D1-6E21-4749-B259-FB2F770A8216Q33961569-318926E0-41C7-4808-A1CA-9FFF98D9ECFEQ34372505-F8FEE7A7-B646-41D7-B933-E966EA5FC3FCQ34989544-79C0C298-F1CF-4624-98AA-FB14DF813115Q35051107-2B779F1C-BDCD-42CC-8CD7-0485880670E1Q35070656-79EF3E64-4ABA-4EC7-87D3-397518DF71D2Q35088131-A65B714B-27D8-45F2-AB68-B9F50715393EQ35499717-BDC33956-0206-4141-901F-2A915D0FC109Q36003320-48D88E51-4871-45BD-B88D-7181E69FAC21Q36073903-057016C1-4B99-4792-90D2-788BC64587F0Q36237952-4A94962D-7F00-46E8-A3C5-6AA7AB2291C0Q36299917-13D8C05A-3956-4C40-827B-B4D4C78E1E05Q36325731-99621B11-8F44-40B9-B126-680B2D7280B6Q36366129-0AF91D51-E385-4A85-B961-D02786991E34Q36423854-57B32714-1949-472C-A04E-AAB536C375CFQ36436893-D81A2320-7B7B-49D7-81EE-B067936042E2Q36476556-AA223DB4-C531-403B-9DC7-8A4236F32026Q36496447-460F58DB-0B3C-498E-B315-EBA6EFDA06C3Q36633444-7DC42D49-EFBD-482E-BD6F-7C0DE7CD6F5CQ36679596-58EEAEB6-9D09-4D40-909B-9EE2EFCDAD3AQ36799806-9B899EDE-EB01-4078-8007-9BCA77C57FD6Q36891269-A9E11F80-72CB-45E4-9DF5-CC6D014CF763Q37000223-0A62C222-25F2-460F-AF5D-C2B1D987B53FQ37235968-17CAA226-F311-4BDF-9DDF-D345DCFDC8F5Q37347851-071F1A53-3AA9-4815-A1EE-17C012C7FEDFQ37687900-2047D9BD-4A45-48B8-A146-B45AC57F15E9Q37803236-FC187DC8-753D-4731-B74B-C09180F41015Q38111803-87EC7497-4BBB-4AA7-A15F-6F96AB9DC9F2Q38762167-CA98950E-F52E-4FBA-8C9D-E002A6CE28D8Q40469488-BF5346AC-95F8-4219-9876-3799DF2E76D7Q40872159-CF1EF028-37CF-4B87-9E17-EF3D3A368D32Q40896042-041BC254-4526-47AD-9A5F-2AC762C1AD29Q41123077-E0DA53C0-062A-482D-9771-330771B1A26DQ41153512-B12638F4-FFD7-44FE-B2A6-CE28E6DFFD7AQ41867898-5CCB222A-D608-4FBD-89C3-F4B9AD3FF0ECQ43818477-88DAD886-665E-4DD5-844B-CB9F3EA9D018Q44418878-53B3FE10-2487-45B8-857F-9D794ECCC9B5
P2860
Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@en
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@nl
type
label
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@en
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@nl
prefLabel
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@en
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@nl
P2093
P356
P1476
Anemia as a risk factor for ca ...... act of chronic kidney disease.
@en
P2093
Andrew S Levey
Dan Pettitt
Daniel E Weiner
Deeb N Salem
Hocine Tighiouart
John Griffith
Mark J Sarnak
Panagiotis T Vlagopoulos
P304
P356
10.1681/ASN.2005030226
P577
2005-09-14T00:00:00Z